Why in news?
A study published on 7 September 2026 identified a specific autoimmune pathway that worsened atherosclerosis in mice. Researchers found an antibody that targets the body’s own histone 2B protein. Related antibody levels were associated with aortic calcification in a human study. The findings suggest a mechanism but do not establish a new treatment.
What is atherosclerosis?
Atherosclerosis develops when plaque builds within artery walls. Plaque contains cholesterol, fat, blood cells, calcium and other material. Growing deposits narrow the passage available for blood. They can affect arteries supplying the heart, brain, kidneys, limbs and other organs.
A plaque may remain silent for many years. If it ruptures, a blood clot can form on its surface. That clot may partly or completely block oxygen-rich blood. The result can include a heart attack, stroke or severe loss of circulation.
The condition is one form of arteriosclerosis, which broadly means thickened or hardened arteries. Age, genes and high blood cholesterol influence risk. Smoking, high blood pressure, diabetes and unhealthy habits also matter. Inflammation has long been recognised as an important part of plaque development.
Why scientists suspected autoimmunity
The immune system normally recognises threats while sparing the body’s own tissues. Autoimmunity occurs when that tolerance fails. Atherosclerotic arteries contain many immune cells and inflammatory signals. Researchers have therefore asked whether specific self-targeting immune responses actively drive disease.
Diseased mouse arteries can develop organised immune structures beside the vessel wall. These are called artery tertiary lymphoid organs. They resemble small local meeting places for immune cells. B cells within them can mature and produce highly selected antibodies.
Earlier evidence linked immunity with atherosclerosis but did not settle every mechanism. An antibody found near a plaque might be a cause, consequence or bystander. Stronger evidence requires identifying its target and testing biological effects. The new research followed that sequence in controlled experiments.
What the researchers found
The team isolated specialised B cells from mouse artery lymphoid structures and lymph nodes. It then cloned sixty antibodies made by those cells. One antibody, called A6, bound strongly to histone 2B. Histones are proteins that help package deoxyribonucleic acid inside cell nuclei.
Damaged or dying cells can expose nuclear material to the immune system. The researchers found histone 2B within plaque-related tissue. They then tested whether the identified immune response changed disease. Both histone vaccination and transfer of A6 accelerated plaque in susceptible mice.
These interventions support a causal role within that mouse model. They do not mean vaccination caused ordinary human atherosclerosis. The animals were genetically prone to plaque formation. Experimental dose, immune conditions and disease timing also differ from everyday human exposure.
What the human evidence shows
The human arm was a cross-sectional study of 495 adults in Guangzhou, China. Participants were aged between thirty and seventy years. Researchers obtained usable three-dimensional chest computed-tomography scans from 418 people. They also measured antibodies against histone 2B in blood samples.
Higher antibody levels were positively associated with calcification in the thoracic aorta. Calcification can reflect an established atherosclerotic burden. A cross-sectional study measures exposure and outcome around the same time. It cannot prove which came first or establish that one caused the other.
The cohort also came from one screening population. The study was not powered to explain possible differences between women and men. Histone 2B responses are not necessarily unique to this disease. Larger and more diverse studies must test prediction, specificity and reproducibility.
Why the mechanism matters
A defined antibody and target provide a clearer path for future research. Scientists can examine when the response begins and which patients show it. They can also test whether blocking that pathway changes disease safely. Any intervention must avoid weakening useful immunity or causing new immune problems.
The finding may eventually improve risk classification or reveal a therapeutic target. Those possibilities remain research questions. No approved test or treatment follows directly from this paper. Animal success alone is insufficient for clinical use.
Existing prevention remains essential during that research. Managing cholesterol, blood pressure and diabetes lowers cardiovascular risk. Avoiding tobacco, staying active and using prescribed medicines also remain important. Patients should not change treatment because of an early mechanistic study.
Conclusion
The study connects a self-reactive antibody with faster plaque formation in a mouse model. Its human arm found an important association, not proof of causation. Together, the results strengthen an autoimmune explanation for part of atherosclerosis. Clinical value will require larger cohorts, independent replication and carefully tested interventions.